Koers Pluristem Therapeutics Inc. Nasdaq
Aandelen
US72940R1023
Biotechnologie & Medisch Onderzoek
Omzet 2022 | 234K 217K | Omzet 2023 | 287K 267K | Marktkapitalisatie | 32,98 mln. 30,65 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -41 mln. -38,1 mln. | Nettowinst (verlies) 2023 | -28 mln. -26,02 mln. | EV/omzet 2022 | 58 x |
Nettoliquiditeiten 2022 | 26,21 mln. 24,36 mln. | Nettoliquiditeiten 2023 | 10,27 mln. 9,54 mln. | EV/omzet 2023 | 79,1 x |
K/w-verhouding 2022 |
-0,96
x | K/w-verhouding 2023 |
-1,04
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 76,12% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yaky Yanay
CEO | Chief Executive Officer | 52 | 01-11-06 |
Director of Finance/CFO | 40 | 01-05-13 | |
Zami Aberman
CHM | Chairman | 70 | 26-09-05 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 73 | 15-07-21 | |
Lorne Abony
BRD | Director/Board Member | 55 | 11-07-23 |
Zami Aberman
CHM | Chairman | 70 | 26-09-05 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,9 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,7 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |